An exciting success story for personalized medicine – Amgen demonstrates that its colon cancer treatment Vectibix works markedly better for patients without a mutated KRAS gene. Whether this drug is worth $8000 a month for you or not can be predicted by a single SNP biomarker.
Posted by: biotechbeachbum | August 11, 2009
Amgen’s Personalized Strategy for Cancer Pays Off in Big Colon Cancer Trial | Xconomy
Posted in Uncategorized
